Pozanicline

DB05458InvestigationalSmall molecule

ABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for the treatment of several neurological disorders including Alzheimer, Attention Deficit Hyperactivity Disorder and Schizophrenia/Schizoaffective disorders. In... In radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR subtypes.

Mechanism: ABT-089 is a neuronal nicotinic acetylcholine receptor agonist. In radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR subtypes.
Curator reviewed
Primary indication: Investigated for use/treatment in Alzheimer's disease, Attention Deficit/Hyperactivity Disorder (ADHD), and Schizophrenia and schizoaffective disorders.Curator reviewed
Formula / weight: C₁₁H₁₆N₂O · 192.2575 g/mol (avg)
Code names: A-87089.0 · ABT-089

Resolves to

Compound

UNIICL2002R563CAS161417-03-4ChEMBLCHEMBL127071PubChem178052

Structure

InChIKeyYRVIKLBSVVNSHF-JTQLQIEISA-NSMILESCC1=C(OC[C@@H]2CCCN2)C=CC=N1

Targets

P17787CHRNB2P43681CHRNA4

What you can answer from here — as of January 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pozanicline, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account